Azizi E, Brenner H J, Shoham J
Arzneimittelforschung. 1984;34(9):1043-7.
37 patients with cutaneous malignant melanoma (MM) were randomized, after surgical removal of tumor, to either no further treatment or to adjuvant treatment by the thymic factor thymostimulin (TS; Tp-1 Serono). 26 patients were with primary (stage I) MM (tumor thickness greater than 1.25 mm), and 11 patients with local or regional disease spread (stage II MM). Randomization was done separately for each disease stage. Life table analysis of the results indicates that significantly (p less than 0.01) more patients were free of disease at one year on study if treated by TS than if left untreated. Probability of survival was also better (p = 0.05) in the TS-treated group at 15 months on study. No side effects, toxic or allergic, were observed under TS treatment.
37例皮肤恶性黑色素瘤（MM）患者在手术切除肿瘤后，被随机分为两组，一组不再接受进一步治疗，另一组接受胸腺因子胸腺刺激素（TS；赛诺菲的Tp - 1）辅助治疗。26例患者为原发性（I期）MM（肿瘤厚度大于1.25 mm），11例患者有局部或区域疾病扩散（II期MM）。每个疾病阶段分别进行随机分组。结果的生命表分析表明，接受TS治疗的患者在研究一年时无疾病的比例显著高于未治疗组（p < 0.01）。在研究15个月时，TS治疗组的生存率也更高（p = 0.05）。在TS治疗过程中未观察到任何副作用、毒性反应或过敏反应。
